We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$42M
Cap. Flow %
-1.57%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.18%
2 Healthcare 9.66%
3 Technology 0.11%
4 Consumer Staples 0.04%
5 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGEN icon
326
PUT
Precigen
PGEN
$2.51B
– –
-1,146
Closed -$2.8M
AGPU
327
Axe Compute Inc
AGPU
$128M
– –
-26
Closed -$298K
PPBT
328
Purple Biotech
PPBT
$2.8M
– –
-116
Closed -$725K
RGLS
329
DELISTED
Regulus Therapeutics
RGLS
– –
-410
Closed -$169K
SAGE
330
DELISTED
Sage Therapeutics
SAGE
– –
-68,950
Closed -$2.81M
SCYX icon
331
SCYNEXIS
SCYX
$43.7M
– –
-7,162
Closed -$1.24M
SVRA icon
332
PUT
Savara
SVRA
$1.08B
– –
-5
Closed -$17K
TEVA icon
333
CALL
Teva Pharmaceuticals
TEVA
$45.7B
– –
-3,618
Closed -$18.2M
TEVA icon
334
PUT
Teva Pharmaceuticals
TEVA
$45.7B
– –
-1,000
Closed -$5.02M
RVNC
335
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-339
Closed -$461K
STAF
336
DELISTED
Staffing 360 Solutions, Inc. Common Stock (DE)
STAF
– –
-46
Closed -$216K
EXPR
337
DELISTED
Express, Inc.
EXPR
– –
-819
Closed -$1.24M
EXPR
338
PUT
DELISTED
Express, Inc.
EXPR
– –
-33
Closed -$5.04M
CGRN
339
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
– –
-133,690
Closed -$1.84M
PRTK
340
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-245
Closed -$341K
INFI
341
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-22,500
Closed -$34.6K
INFI
342
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-225
Closed -$30K
KDNY
343
CALL
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-264
Closed -$1.5M
CLVS
344
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-59,836
Closed -$1.28M
GBT
345
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-254,029
Closed -$4.84M
ATRS
346
DELISTED
Antares Pharma, Inc.
ATRS
– –
-424,100
Closed -$445K
ADXS
347
DELISTED
Advaxis Inc
ADXS
– –
-933
Closed -$113K
ADXS
348
PUT
DELISTED
Advaxis Inc
ADXS
– –
-9
Closed -$113K
KTOVW
349
DELISTED
Kitov Pharma Ltd. Warrants
KTOVW
– –
-1,210,785
Closed -$944K
MNTA
350
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-145,600
Closed -$1.71M
11 12 13
14
15

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management's Q3 2016 filing shows 93 new, 88 increased, 106 reduced and 73 closed positions. Its largest new stake was Bristol-Myers Squibb: 156,887 shares worth $8.46M. The largest sale was Sarepta Therapeutics, an estimated $7.47M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, up from 86% a quarter earlier, followed by Healthcare and Technology.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.